Takeda is pleased to announce that DEXILANT™ (dexlansoprazole) is now available in Canada. DEXILANT is the first and only proton pump inhibitor (PPI) with a novel DUAL DELAYED RELEASE technology, which delivers two separate doses of medication at different times providing improved and sustained symptom relief throughout the day and night. DEXILANT delayed release 30 mg and 60 mg capsules are indicated as a once-daily oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis and the maintenance of healed erosive esophagitis. GERD, a chronic condition commonly known as acid reflux disease, affects one-third of the Canadian population and is often characterized by frequent and persistent heartburn that occurs two or more days a week1.

"Takeda is focused on health care solutions that address the unmet medical needs of patients," says Paul Friel, general manager and president, Takeda Canada, Inc. "We are thrilled that doctors can now prescribe DEXILANT as part of an overall plan to help patients better manage and better control erosive esophagitis and symptoms of GERD."

DEXILANT OR DUAL DELAYED RELEASE is a trademark of Takeda Pharmaceuticals North America, Inc. and used under liscense by Takeda Canada.

[1] Canadian Society of Intestinal Research. GERD

Source: Takeda Pharmaceutical